Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Withdrawn 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 642pembrolizumab 565Magnetic Resonance Spectroscopy 548Carboplatin 426Cisplatin 377Cyclophosphamide 374Biopsy 365Paclitaxel 306Nivolumab 303Gemcitabine 303Radiotherapy 274Bevacizumab 240Dexamethasone 209fludarabine 207Docetaxel 191durvalumab 183atezolizumab 177Oxaliplatin 174venetoclax 168Fluorouracil 167Rituximab 166Pemetrexed 164Capecitabine 161Radiation 159Doxorubicin 159Radiosurgery 150Etoposide 137Ipilimumab 135Leucovorin 133Lenalidomide 132

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
bemarituzumab × 90 days × Clear all
NCT05052801 2026-05-27

FORTITUDE-101

Amgen

Phase 3 Completed
547 enrolled
Gastrointestinal

Stomach Neoplasms

NCT07146919 2026-04-23

ANGELICA

Centre Leon Berard

Phase 1/2 Withdrawn
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07470840 2026-03-24

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Fujian Cancer Hospital

Phase 2 Not yet recruiting
27 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡